POSTER SESSIONS Journal of Thoracic Oncology

POSTER SESSIONS Journal of Thoracic Oncology
Journal of Thoracic Oncology Volume 10, Issue 9, Pages S407-S760 (September 2015) DOI: /S (16) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S407-S760DOI: (10
Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 A) Proportion of patients receiving systemic therapy
B) Overall survival for all patients by physician. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Kaplan–Meier estimates of overall survival

Figure 2 Kaplan-Meier survival curves by EZH2 nuclear expression

Fig 1 Freedom from recurrence in patients with MIP/SOL

Table 1 Multiple Lung Cancer: Molecular Data

Figure 1 Central Memory T-cells in patient pbmc's pre- and post-SAR

Figure 1 Overall survival in PP population. Overall survival in the PP population of a total of 27 patients. Median overall survival was 35.5 months (95% Cl: months). Overall survival at 1-, 2- and 3-years was 71.0% (95% Cl: 52.8 – 80.3%), 50.1% (95% Cl: 28.3 – 61.2 %) and 25.1% (95% Cl: 0 – 43.7%) Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Progression-free survival in PP population. Progression free survival in the PP population of a total of 27 patients. Median progression free survival was 20.8 months (95% Cl: months). Overall progression-free survival at 1-, 2- and 3-years was 55.6% (95% Cl: %), 25.9% (95% CI: 4.5 – 36.8 %) and not reach. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Strong hyaluronan (FIA) signal at the epithelial cell-extracellular matrix interface (B) in normal lung (A), coincident with regular microvessels staining (C), absence of colocalization at confocal microscopy (D) and low signal when compared to tumoral tissue (E). High expression (>48%) of HA in squamous cell carcinoma (SqCC) (F) on cancer cells-stroma interface (G), coincident with high microvessel (>33%) staining foci (H), identical colocalization at confocal microscopy (I) and higher signal when compared to normal tissue (J). HA-negative in normal lung (K) and cells of adenocarcinoma (AD) (L); note the strong HA staining in tumor stroma (L), coincident with microvessels staining (M), foci of colocalization at confocal microscopy (N) and higher expression compared to normal tissue (O). Very poor signal in normal lung (P) and in large cell carcinoma (ICC) (Q); note strong HA foci staining (Q), coincident with focal microvessels density (R), focal colocalization at confocal microscopy (S) and low signal when compared to normal tissue (T). Arrowheads indicate stromal tissue; asterisks indicate carcinoma cells. H&E; hematoxylin and eosin; MVD: microvessel density. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Comparison of Epithlioid and Biphasic cell types.

Fig 1 Diffuse nodular (left) and dendriform (right) pulmonary ossifications. Nodular ossifications grow within the alveolar spaces, where dendriform ossifcations branch through the septa and often contain fatty bone marrow. (H&E stain, 400x) Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Histology Incidence Trends by Race/Ethnicity

Figure 1 MFN2 regulates lung adenocareinoma cell proliferation and invasion (A) Represemative images for MFN2 expression on lung adcnocareinomations of two patients. (B) Quantification of MFN2 expression status in lung adenocarenoma adjacent normal issues. (C) Cell proliferation changes in A549 cells treated with MFN2 shRNA. (D) Cell invasion ability in A549 cells treated with MFN2 shRNA. (E) Cell cycle changes in A549 cells treated wtih MFN2 shRNA. (F) Heatmap of gene gene expression profile in A549 cells treated wtih MFN2 shRNA. (G) Funetional pathway enrichment of dercgulned gents in A549 cells treated with MFN2 shRNA. (H) Confirmation of deregulated genes in A549 cells trated with MFN2 shRNA by western blot. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 (A) RT-PCR of ASCL1 mRNA in the disstal airways of 8 cancer-free subjects grouped according to smoking status. Difference in ASOL1 mRNA titers among me three groups did not reach statistical significance (p = 0 26) 1Data available for only one never-smoker (n=1). (B) Western blot band intensity (ASCL1/1damai B1) of A549 cels treated with cigarette smoke condensate (CSC). 1% DMSO or serum-free media (SF). A 4-hour exposure to 10 mcg/mL CSC led toa 4 1 fold increase in ASCL1 expression compared to 1% DMSO (p = 0 023) and a 2 0 fold increase compared to SF (p = 0.017). Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Involvement of MLF1IP in lung adenocarcinoma
(A) Expression status of MLF1IP mRNA in lung adenocarcinoma. (B) Cell proliferation in A549 cells treated with MLFlIP shRNA by Cellomics cell counting methods. (C) Cell proliferation in A549 cells treated with MLF1IP shRNA by MTT assay. (D) Colony formation ability in A549 cells treated with MLF1IP shRNA. (E) Cell cycle status in A549 cells treated with MLF1IP shRNA. (F) Cell apoptosis in A549 cells treated with MLF1IP shRNA Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Percentage of screening participants for whom re-assignment of lung cancer risk score category occurred when their individualised SNP genotype data (genetic risk score) was added to the clinical data to derive the overall risk category. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 miRNAs expression differences. A. Comparison of miRNAs expression in patients with different stages of NSCLC and SCLC as well as in healthy individuals. B. Expression of miR-944 and miR-3662 in early stages of NSLC and in healthy control. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 ROC analysis of studied miRNAs in NSCI.C patients and their diagnostic accuracy: A - ROC for combination analysis of both miRNAs for distiagulshing early stages of NSCLC from healths control, B - ROC for analysis of miR-944 for distinguishing early stages of SCC from healthy control, C - ROC for analysis of miR-3662 for distinguish early stages AC from healthy control. Diagnostic power of analysis was shown as an AUC calculation as well as sensitivity and specificity of each ROC curves. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Overall survival in small cell lung cancer patients with NLR ≥4 versus NLR <4 (log-rank P=0.014) Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Kaplan-Meier Survival Curves

Figure 1 Adenocarcinoma of the Lung: Survival in Months by Treatment Group Erlotinib Treatment versus Non-Erlotinib Treatment Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Fatigue Incidence and Worsen of Fatigue by Maintenance Cycle. Incidence of CTCAE grade 1/2 and grade 3/4 fatigue for overall (A) and East-Asian (B) patients in the pemetrexed and placebo treatment arms for maintenance cycles 1 through 10. Worsening of fatigue based on the patients-reported LCSS scores for overall (C) and East-Asian (0) patients in the pemetrexed and placebo treatment arms for maintenance cycles 1 through 10. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Patients demographic characteristics and propensity score-matched characteristics between two groups. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 A.0ptimal cutoff values of the TTAC by maximally selected log-rank statistics. Kaplan-Meier curve for NSCLC disease-free survival(DFS) according to interval between surgery and chemotherapy initiation. B. In all patients, there was significant difference in the DFS between patients who received adjuvant chemotherapy within 50 days and later than 50 days(P=0.005). C. In propensity score-matched pairs, DFS was not significant difference between the 2 groups(P=0.122). Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Availability of EGFR test in routine practice

Figure 1 Kaplan-Meier Curve.

Figure 1 Kaplan-Meier curve. Table 1. Subgroup analyses

Fig. 1. Two Group OPLS Clustering Analysis. VOC profile differences between CON (Other lung diseases) and Lung cancer Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 2. Three Group OPLS Clustering Analysis. VOC profile differences among CON (Other lung diseases), Lung cancer and TB (Tuberculosis). Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 1. Comparative analysis of overall survival curves between radiographically detected [chest radiography (CXR)] non-small cell lung cancer patients and symptom-prompted patients. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4. CK2α downregulation suppresses SCLC cell motility in the wound healing assay (magnification, ×200). Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

figure 1 the PFS and different gene type

figure 2 the OS and different gene type

Fig. 1 Kaplan-Meier curves for progression-free survival by treatment group Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Fig. 2 Kaplan-Meier curves for overall survival by treatment group

Figure 1 Patients demographic characteristics and propensity score-matched characteristics between two groups. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Kaplan-Meier plot for NSCLC disease-free survival (DFS) according to age. A. In all patients there was no significant difference in the DFS between younger patients (age≤6S years) and older patients(age >65 years) (P–0.951) B. In propensity score-matched pain. DFS was not significant difference between the 2 groups(P–0.731) Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Kaplan Meier survival curve for above and below median melatonin concentration. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Kaplan-Meier survival curves by EZH2 nuclear expression

Figure 4 Kaplan-Meier curve of overall survival at 1 year according to CD117 expression (n=46) Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Stage shift according to screening arm (CXR vs CT) in the NLST-ACRIN substudy (N=18,714) after stratification by COPD status. Journal of Thoracic Oncology , S407-S760DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

POSTER SESSIONS Journal of Thoracic Oncology

Similar presentations

Presentation on theme: "POSTER SESSIONS Journal of Thoracic Oncology"— Presentation transcript:

Similar presentations

About project

Feedback

Log in

Auth with social network:

POSTER SESSIONS Journal of Thoracic Oncology

Similar presentations

Presentation on theme: "POSTER SESSIONS Journal of Thoracic Oncology"— Presentation transcript:

Similar presentations

About project

Feedback